ENANTA PHARMACEUTICALS, INC Deferred Income Tax Assets, Net
ENANTA PHARMACEUTICALS, INC (ENTA) had Deferred Income Tax Assets, Net of $345.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2021-11-24
- 2021-06-30: Deferred Income Tax Assets, Net $345.00K.
- 2021-03-31: Deferred Income Tax Assets, Net $345.00K.
- 2020-12-31: Deferred Income Tax Assets, Net $345.00K.
- 2020-09-30: Deferred Income Tax Assets, Net $345.00K.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2021-06-30 | $345.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $345.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $345.00K 10-Q · filed 2021-02-09 |
| 2020-09-30 | $345.00K 10-K · filed 2021-11-24 |
| 2020-06-30 | $15.29M 10-Q · filed 2020-08-10 |
| 2019-09-30 | $11.34M 10-K · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |